Covalon Technologies

Covalon Technologies FCF Yield

The Free Cash Flow Yield of Covalon Technologies (COV.V) as of Oct 16, 2026 is 2.95 %. In the previous year, Free Cash Flow Yield was 6.25 % — a change of -52.81% (lower).

FCF Yield

2.95 %

YoY

-52.81%

Last updated:

Free Cash Flow Yield of Covalon Technologies is 2025 2.95 % . Free Cash Flow Yield of Covalon Technologies was 2024 6.25 % . It decreases by -52.81% lower compared to the previous year.

The Covalon Technologies FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-2.85 CAD
Jan 1, 2019
-8.41 CAD
Jan 1, 2020
-8.99 CAD
Jan 1, 2021
0.91 CAD
Jan 1, 2022
-18.57 CAD
Jan 1, 2023
-9.21 CAD
Jan 1, 2024
6.25 CAD
Jan 1, 2025
2.95 CAD
The Covalon Technologies FCF Yield history
YEARFCF YieldYoY
2.95 %-52.81%
6.25 %-167.91%
-9.21 %-50.41%
-18.57 %-2,145.35%
0.91 %-110.09%
-8.99 %+7.00%
-8.41 %+194.44%
-2.85 %+305.04%
-0.70 %-73.03%
-2.61 %-49.06%
-5.13 %-184.03%
6.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Covalon Technologies Stock analysis

What does Covalon Technologies do? Covalon Technologies Ltd, listed on the TSX Venture Exchange under the ticker COV.V, is a biotechnology company based in Mississauga, Ontario, Canada. Founded in 2004, the company went public on September 3, 2004, with its initial public offering. Covalon specializes in the research, development, manufacturing, and marketing of patent-protected medical products. The company focuses on advanced wound care, infection prevention, and medical device coatings, offering solutions designed to reduce infections, minimize pain, and improve patient outcomes. Its products include specialized medical devices, medical dressings, and advanced technologies for perioperative care, antimicrobial skin protection, and complex wound closure. Covalon operates through two primary business models: developing and selling its own branded products and collaborating with other medical companies through development and licensing agreements. The company emphasizes compassionate care, creating products that are both patient-friendly and tailored for healthcare providers. Headquartered in Mississauga, Covalon leverages its patented technology platforms to address critical needs in medical care, particularly in reducing post-surgical infections and enhancing recovery processes. The company's solutions are intended to support both patients and medical professionals by providing effective, innovative approaches to wound management and infection control. Covalon's portfolio reflects a commitment to advancing medical technology with a focus on practical, patient-centered applications. Covalon Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Covalon Technologies stock

Free Cash Flow Yield of Covalon Technologies is 2.95 % in 2025.

Free Cash Flow Yield of Covalon Technologies changed from 6.25 % to 2.95 %, representing a -52.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Covalon Technologies since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Covalon Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Covalon Technologies

All Key Metrics — Covalon Technologies